About Anthrax toxin receptor 2
Anthrax toxin receptor 2 (ANTXR2) is a protein
from Homo sapiens identified by UniProt accession
P58335, 489 residues long.
MolForge cross-references it against 0 known binders and
222 disease associations.
Target properties
| Protein name | Anthrax toxin receptor 2 |
| UniProt accession | P58335 |
| Gene | ANTXR2 |
| Organism | Homo sapiens |
| Length | 489 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (222)
Diseases linked to this target (Open Targets).
- hyaline fibromatosis syndrome · score 0.80
- anthrax infection · score 0.56
- lymphocyte count · score 0.48
- juvenile hyaline fibromatosis · score 0.46
- leukocyte count · score 0.44
- Myopia · score 0.38
- age at onset · score 0.37
- infantile systemic hyalinosis · score 0.37
- refractive error · score 0.37
- lymphocyte percentage of leukocytes · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P58335-F1 | alphafold | PREDICTED | 71.82 | — |
Amino-acid sequence (489 residues)
MVAERSPARS PGSWLFPGLW LLVLSGPGGL LRAQEQPSCR RAFDLYFVLD KSGSVANNWI EIYNFVQQLA ERFVSPEMRL SFIVFSSQAT IILPLTGDRG KISKGLEDLK RVSPVGETYI HEGLKLANEQ IQKAGGLKTS SIIIALTDGK LDGLVPSYAE KEAKISRSLG ASVYCVGVLD FEQAQLERIA DSKEQVFPVK GGFQALKGII NSILAQSCTE ILELQPSSVC VGEEFQIVLS GRGFMLGSRN GSVLCTYTVN ETYTTSVKPV SVQLNSMLCP APILNKAGET LDVSVSFNGG KSVISGSLIV TATECSNGIA AIIVILVLLL LLGIGLMWWF WPLCCKVVIK DPPPPPAPAP KEEEEEPLPT KKWPTVDASY YGGRGVGGIK RMEVRWGDKG STEEGARLEK AKNAVVKIPE ETEEPIRPRP PRPKPTHQPP QTKWYTPIKG RLDALWALLR RQYDRVSLMR PQEGDEVCIW ECIEKELTA
Explore Anthrax toxin receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets